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Abstract
Rare diseases pose specific challenges in the field of medical research to provide 
physicians with evidence-based guidelines derived from studies with sufficient quality. 
An example of these rare diseases is multiple endocrine neoplasia type 1 (MEN1), which 
is an autosomal dominant endocrine tumor syndrome with an estimated occurrence 
rate of 2–3 per 100,000. For this complex disease, characterized by multiple endocrine 
tumors, it proves difficult to perform both adequate and feasible studies. The opinion of 
patients themselves is of utmost importance to identify the gaps in the evidence-based 
medicine regarding clinical care. In the search for scientific answers to clinical research 
questions, the aim for best available evidence is obvious. Observational studies within 
patient cohorts, although prone to bias, seem the most feasible study design regarding 
the disease prevalence. Knowledge and adaptation to all types of bias is demanded 
in the strive for answers. Guided by our research on MEN1 patients, we elaborate on 
strategies to identify sufficient patients, to maximize and maintain patient enrolment 
and to standardize the data collection process. Preferably, data collection is performed 
prospectively, however, under certain conditions, data storage in a longitudinal 
retrospective database with a disease-specific framework is suitable. Considering the 
global challenges on observational research on rare diseases, we propose a stepwise 
approach from clinical research questions to scientific answers.
Introduction
Rare diseases that affect less than one in 2000 people, 
pose challenges in supporting patients and physicians 
with evidence-based guidelines of sufficient quality (1). 
Medical decision making becomes challenging when 
guidelines are scarce or the underlying scientific evidence 
is meager.
Multiple endocrine neoplasia type 1 (MEN1) (OMIM 
131100) is an autosomal dominant disease with an 
estimated occurrence rate of 2–3 per 100,000 (2). Due to 
the complexity of the disease, which is characterized by 
the development of multiple endocrine tumors already 
at an early age, developing evidence-based guidelines is a 
challenge (3). Most patients suffer from the classical triad of 
primary hyperparathyroidism (pHPT), duodenopancreatic 
neuroendocrine tumors (dp-NETs) and/or pituitary 
adenomas. The prevalence for pHPT, dp-NETs and 
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pituitary tumors are 87, 56 and 44%, respectively in the 
Dutch population (4). Other encountered neoplasms 
include adrenal tumors, neuroendocrine tumors (NETs) of 
thymic, bronchial or gastric origin, skin and subcutaneous 
tumors, smooth muscle tumors and breast cancer (5, 6). 
Life expectancy of MEN1 patients is reduced compared 
to the general population (4). The prognosis of patients 
depends on early tumor detection and subsequent targeted 
interventions to prevent disease progression, making 
lifelong screening and intensive monitoring necessary (7).
Randomized controlled trials studying interventions 
and the optimal follow-up are almost impossible because 
of the low number of eligible patients for inclusion as 
well as the low yearly incidence of events in individual 
patients. Cohort studies are prone to various forms of bias 
such as selection bias, information bias and confounding 
by indication (8, 9).
Confronted by the principles of evidence-based 
medicine and need for high-quality scientific evidence 
regarding follow-up and interventions in MEN1, in the 
Netherlands in 2007, a retrospective MEN1 database 
was carefully designed. The aim was to answer multiple 
research questions that were based on the clinical dilemmas 
MEN1 patients and their treating physicians encountered 
in daily practice. The aim of this project was to provide 
patients and physicians with valid data. Considering 
the complexity of MEN1, a longitudinal database with 
a disease-specific framework was a necessity. Whereas 
strategies for conducting randomized controlled trials on 
rare diseases have been described, research methods for 
observational studies are far less developed (10). Guided 
by the fruitfulness of our longitudinal database and 
experience on this topic, this article will elaborate on our 
research strategy and observational study methods for 
rare diseases, describing the stepwise process from clinical 
research questions to scientific answers.
Clinical dilemma and theoretical 
study design
Formulating research questions and determining 
study design
Biomedical research consists of three main phases: 
formulating a research question, the collection of data 
based on these questions and the analysis of data. In 
recent years, the importance of the opinion of patients 
affected by the disease in this process is increasingly 
acknowledged. The subsequent study design is guided by 
a well-structured research question, addressing the study 
domain (patients with symptoms or a certain disease), 
determinant (diagnostic test, factor or therapy) and 
outcome of interest.
MEN1 formulated research questions
Clinical guidelines are only as good as the evidence 
and judgments they are based on (11). Even though 
there was a MEN1 consensus statement at the time, 
the scientific evidence underlying recommendations 
regarding screening and treatment of the different MEN1 
manifestations was not always sufficient (12).
Our research group was confronted by a paucity 
of data on the natural course of the different MEN1 
manifestations, prognostic factors, a genotype–
phenotype relation, the timing and effect of therapy and 
recommendations based on strong evidence for periodical 
screening for these manifestations. These topics were 
the basis of the first set of research questions (Table  1). 
In addition, we consulted the patient advocacy group 
in this stage of the process, as to which questions they 
deemed important to study. The patient advocacy group 
considered quality of life as an important topic to study. 
More specifically, they considered questions regarding 
frequency and content of follow-up visits, effects and 
complications of surgery (e.g. hypoparathyroidism after 
(sub)total parathyroidectomy) and survival of dp-NETs 
as important topics since these affect quality of life. In 
a process of informed shared decision-making, research 
questions and study aims were formulated thereafter.
Study population
A single center patient population
In the University Medical Center (UMC) Utrecht, 
approximately 80 MEN1 patients were identified in 
2007, which can be regarded as a ‘large’ rare disease 
population. However large, this study population lacked 
power to detect meaningful differences. In addition, we 
considered the population as a possible source of selection 
bias, since our center is a national center of expertise in 
MEN possibly leading to a case-mix with more advanced 
stages of the disease. Improper selection of patients, not 
being representative for the target population, leads to 
selection bias. In general, minimizing selection bias is 
attempted by including as many patients as possible in 
terms of percentage from similar hospitals, regarding level 
of patient care, during the recruitment phase.
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Collaboration at a national level
In the Netherlands, MEN1 patients are commonly treated 
in a UMC (tertiary referral center) because of the necessity 
of a trained and dedicated multidisciplinary team (13). To 
include a representative sample of MEN1 patients and to 
increase sample size, a nationwide collaboration, known 
as the DutchMEN Study Group (DMSG), was initiated in 
2008 (14). The DMSG consists of endocrinologists from 
every Dutch UMC, a consulting endocrine surgeon and 
representation from the patient advocacy group. Moreover, 
other specialist members of the multidisciplinary team are 
closely involved, which is in line with MEN1 guidelines to 
optimize patient care (13). The DMSG program, including 
patients from all Dutch UMCs, has led to the inclusion 
of over 90% of the total Dutch MEN1 population (> 400 
participants) making it a true representation of Dutch 
MEN1 patients (15).
Patient identification
Before enrolling patients, a consistent diagnosis in 
accordance with guidelines is important. In this manner, 
a restricted population is created and selection bias is 
minimized. Using a standard identification method, 
MEN1 patients were identified by hospital diagnosis 
databases review. MEN1 diagnosis was based on clinical, 
familial or genetic criteria, based on clinical practice 
guidelines (12, 13). Less than 10% of the genetically 
diagnosed MEN1 patients is not included in the registry 
and only one person refused to participate. The high 
participation rate (over 90%) has also been found in a 
survey of patients with leukodystrophies, another rare 
disease (16). However, for MEN1 populations, this registry 
participation rate is globally unique and thereby leading 
in the field.
Strategies to maximize patient enrolment
The urge for international data registries is expressed 
by The European Union Committee of Experts on Rare 
Diseases (17). Patients with rare diseases are generally 
easily accessible for participation in international data 
registries (16, 18). Since MEN1 is an autosomal dominant 
trait, patients’ children have a 50% chance of inheriting 
the disease (2). Patients are well aware of the high disease 
morbidity and decreased life expectancy since the disease 
‘runs in the family’. Patients maximize their contribution 
to medical research and subsequent clinical care for their 
affected relatives and other MEN1 patients.
Nevertheless, before patients are willing to engage 
in medical research, the physician–patient interaction 
is important (16, 19). In addition, to enroll a maximum 
number of patients, the study goals should be of direct 
importance to patients and their families. Active 
involvement of the national patient advocacy group in the 
DMSG from the stage of designing the research questions 
contributed to the high participation rate of patients.
Obtaining informed consent
The study protocol for the DMSG database and subsequent 
studies was approved by the Medical Ethical Committees 
of all UMCs in the Netherlands. The requirement to 
obtain individual informed consent was waived because 
of the retrospective and observational design. However, 
all patients received a letter including information 
regarding the collection and storage of clinical data and 
the possibility to refuse. From 2016 onward, the clinical 
database was continued prospectively including the 
collection of biobank materials (clinical biobank). Before 
inclusion in the clinical biobank, patients are informed by 
telephone or during an outpatient clinic visit including 
written patient information and asked to provide written 
informed consent. In addition, patients are informed 
about the possibility to withdraw their informed consent 
at any given time in the future.
Strategies to maintain patient participation
Studies with a necessary long-term follow-up are vulnerable 
to losing patients during follow-up. This potentially leads 
to follow-up bias, especially when the loss to follow-up 
differs between groups. Since MEN1 is a chronic disease 
in which patients have an ongoing risk for tumor 
development, patients consult endocrinologists annually, 
reducing follow-up bias to a minimum. However, patients 
that move to another place might change academic 
treatment center, decide to transfer to a local hospital or 
quit the follow-up regimen altogether. With respect to 
the nationwide collaboration of all Dutch UMCs in the 
DMSG, loss to follow-up of patients is mostly prevented. 
Changing academic center will not end nor interrupt 
data collection, because registry entry will continue 
from the new treatment hospital. Nevertheless, effort 
must be made to ensure regular physician consultations. 
DMSG strategies to minimize loss of follow-up include 
the physician–patient relation, and moreover, regular 
physician consultation is also promoted by the patient 
advocacy group.
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Strategies to establish the study population of the 
Dutch MEN1 registry are summarized in Table 2.
From patients to data
The importance of data collection
The goal of the data collection process is to gather data which 
give true and objective reflections of patients’ conditions. 
Incorrect data or inconsistent data collection leads to 
information bias; therefore, the process of data collection 
must be carefully designed, conducted and preferably 
secured. Before the actual collection of data, it is important 
to understand the nature of the data, to classify the data and 
to decide to which extent data are collected. The quality of 
data is guided by validity and precision. Systematic errors in 
data collection are dangerous, since these lead to irreversible 
damage to the study’s internal validity (20).
Database design
The construction of a structured database and the valid 
and precise collection of data were critical research steps 
(Table 3). Even though some single-center MEN1 studies 
were conducted in the UMC Utrecht, a well-structured 
process of data collection was absent (21, 22). In addition 
to the nationwide expansion of the study population, 
multicenter, nationwide collaboration on data collection 
was essential. Considering the urge for quick answers 
to clinical questions and the low disease prevalence, 
studies with prospective data collection seemed utopia. 
Therefore, a retrospective database was the first step to 
answer multiple research questions.
After setting the basis for national multi-institutional 
data gathering, the actual process of data collection 
and storage, based on national consensus, was the next 
step. Since multiple research questions were formulated 
for different MEN1 manifestations, a database to store 
Table 2 DMSG study population strategies.
Study step Recommendation
Sample size and minimize selection 
bias
– Nationwide collaboration
– Including comparable hospitals, e.g. tertiary referral centers
– Multicenter research
– Start (supra)national study group
Patient identification – Consistent diagnosis according to guidelines
– Standardized identification method in hospital diagnosis databases
Patient enrolment – Formulate study goals that are of direct importance to patients
– Patient advocacy group involvement from the start
Recruitment of patients among members
 ⚬ Prioritize research agenda/study questions
 ⚬ Provide information among members/patients
 ⚬ Familiarize medical research among members
 ⚬ Yearly national and regional patient and specialist meetings
– Disease biology
 ⚬ Autosomal dominant disorder
 ⚬ Families willing to help affected relatives
 ▪ Knowledge on morbidity and mortality
 – Informed consent
Patient participation 
 
 
 
 
 
 
 
 
 
 
 
 
 – Routine clinical care
 ⚬ Trained and dedicated multidisciplinary treatment team
 ⚬ One contact person for each institute
 ⚬ Physician-patient relation
 ⚬ Annual clinical consultation due to risk of tumor onset
 – In case of hospital change
 – Nationwide collaboration
 – Continue registry in new treatment center
 – International workshop on Multiple Endocrine Neoplasia (WorldMEN 2016, Utrecht, 
The Netherlands) including patient sessions
 – Patient advocacy group
 ⚬ Promote annual clinical consultation
 ⚬ Yearly national and regional patient and specialist meetings
 ⚬ Distribute research findings among patients
 ⚬ Formulate new patient oriented questions
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individual patient data was carefully designed according 
to the disease characteristics and the formulated research 
questions. Many research questions addressed the 
frequency and timing of screening, thus knowledge of the 
natural history was demanded. Longitudinal data provide 
insight in the natural disease course. Therefore, data were 
collected retrospectively every quarter from 1990 to 2016.
This longitudinal, retrospective design was further 
developed to a MEN1 disease-specific framework. 
MEN1 patients have a lifetime risk to develop multiple 
endocrine tumors in multiple organs, each with a 
different penetrance. Since, there is no clear age-related 
penetrance for every manifestation and manifestations 
can occur at any given age, lifelong screening for all 
MEN1 manifestations is required (7, 23). Consequently, 
the process of diagnosis, therapy and follow-up is 
an ongoing, repeated and simultaneous process for 
MEN1-related neoplasms.
Variable selection
In line with the disease’s complexity, a wide range 
of variables needed to be included in the database. 
Annual consultations include clinical and biochemical 
screening by specialized endocrinologists. Hormonally 
active tumors secrete different hormones, depending 
on the tumor’s origin. Therefore, biochemical screening 
ranges from 72-h fast tests for pancreatic insulinomas to 
serum calcium levels for primary hyperparathyroidism. 
Radiological screening differs both in frequency and 
modality for different manifestations (13). Extensive 
additional diagnostic procedures may be performed when 
patients are suspected of a manifestation. Therapeutic 
interventions range from medical treatment to surgical 
resections, guided by manifestation, patient characteristics 
and disease stage.
Based on these factors and the formulated research 
questions a dataset was developed for each specific 
MEN1 manifestation (pHPT, dp-NETs, pituitary tumors, 
NETs (of stomach, bronchus and thymus) and adrenal 
lesions) including biochemical, radiological, surgical and 
pathology data (Table 4). Besides, datasets for general data 
on patient characteristics, medication use and previous 
medical history were designed. Multiple versions of 
these datasets were discussed among the study group 
participants and thereafter the final, total dataset was 
agreed upon.
Ahead of the collection of biochemical data from 
multiple hospitals, the planning on ‘how to’ collect 
these variables is essential, since clinical laboratories 
often harbor different measurement methods, leading 
to different units of measurement and reference 
values. Therefore, involvement of clinical chemistry 
laboratories of all participating centers is important 
during the design of the database. In addition, to 
compare these values during data analysis, a useful 
strategy is to express the values as upper level of the 
normal of the reference value, which is widely used in 
medical research.
Data collection
Variations during the data collection process, also known 
as observer bias, are remarkably reduced by securing 
the data collection process, minimizing the number 
of data collectors and collecting only uninterpreted or 
‘raw’ data to prevent interpretation before statistical 
analysis. For example, there was no variable ‘primary 
hyperparathyroidism’ but, to define this variable, the 
outcomes of serum calcium and parathyroid hormone 
levels were used, so data were collected without 
knowledge of the outcomes. In addition, outcomes 
had to be subsequently found in individual patients 
during data analysis, hereby including the repetitive 
identification of a tumor over time as the reference 
standard for the diagnosis of a tumor (24). A central 
protocol was developed, which described per variable 
how it should be collected, so data collectors would 
gain familiarity with the appropriate gathering of 
data and interobserver variations were reduced. In the 
database, constraints were implemented for the range of 
outcomes that could be collected, preventing mistakes 
in data collection because of typing errors. Although 
the data collection in multicenter studies is commonly 
performed by researchers from every institution, only 
one or two centrally appointed data collectors were 
operating at a time. This minimized differences in 
data collection and enabled the collectors to gain vast 
experience in this large dataset, reducing intraobserver 
variability. The ideal geography of the Netherlands 
and centralizing the DMSG from Utrecht, optimized 
this way of data collection. All uncertainties during 
data collection and data capture were discussed with 
one principal investigator, which minimized defaults 
in these areas. These uncertainties were stored and 
are assessable at the present and in the future for the 
data collectors and researchers. The importance of 
protocolized data collection is the gathering of complete 
data, structurally the same in every center and for every 
patient, irrespective of disease severity.
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Data storage
Nowadays, the use of an easily accessible electronic, web-
based application facilitates the collection of data in 
multicenter studies. However, security issues regarding 
patient data are of utmost importance. Concerning 
confidentiality, patients were pseudo-anonymized upon 
inclusion in the database, where every patient received a 
unique identification code, which is available for future 
data collection at the participating hospital. Regarding 
the low disease prevalence, all dates were converted 
into a quarter of a year (e.g. 1 Q 2010 for all dates 
from January 1 up to and including March 31, 2010). 
In addition to the simplification of data collection, 
electronic registries offer the opportunity of direct data 
output for all involved researchers.
Missing data
Retrospective studies are vulnerable for missing data, 
which lead to bias if the missing data are related to the 
outcome or exposure of interest. By securing the data 
collection, the quarterly collection of data and the 
available data from annual consultations, missing data 
Table 3 DMSG recommendations for data storage and data collection.
Study step Recommendation
Data storage  – Web-based database
 ⚬ Easily accessible from every hospital during data collection
 – Confidentiality
 ⚬ Pseudo-anonymize patients
 ⚬ E.g. convert dates to quarters (e.g. 1 Q 2010 for all dates from January 1st up to and including 
March 31st 2010)
Database design  – Urge for relatively quick answers
 ⚬ Retrospective database design
 – Study group consensus on database design
 – Research questions on natural course of disease
 ⚬ Longitudinal database design
 ⚬ Quarterly collection of data
 – Develop a disease-specific framework
 – Epidemiological background: diagnostic, etiologic, prognostic and/or therapeutic aims
 – Longitudinal design
 ⚬ Repetitive collection of the same variables
Variable selection  – General data and considerations
 ⚬ General patient data or demographics
 ⚬ Raw or primary data
 ⚬ Complex diseases and multiple research questions: more variables demanded
 – Select disease-related variables
 ⚬ Screening programs
 ⚬ Different disease manifestations
 ⚬ Biochemical, radiological, surgical and pathology data
 – Study group consensus on variables
 – Plan on how variables, such as laboratory values, should be collected in different hospitals
 – Plan on how the ‘raw’ data can potentially be analyzed
Data collection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 – General steps
 ⚬ Collect raw data
 ⚬ Compulsory variables
 ⚬ Implement constraints in the database
 ⚬ Data capture control among data collectors
 ⚬ One principal investigator
 ▪ Discuss uncertainties
 ▪ Document and store these decisions
 – Develop a central protocol to facilitate standardized data collection
 ⚬ Data are consistently captured appropriately
 – Minimize number of data collectors at a time
 ⚬ Data collectors will gain familiarity with the database
 ⚬ Select data collectors with affinity for the project, e.g. PhD students using the data for their 
thesis
 ⚬ Provide data collectors with enough time to collect data
This work is licensed under a Creative Commons 
Attribution-NonCommercial-NoDerivatives 4.0 
International License.
https://doi.org/10.1530/EC-18-0359
https://ec.bioscientifica.com © 2018 The authors
Published by Bioscientifica Ltd
D-J van Beek et al. ‘Quality in, quality out’ EBM 
promoted by MEN1
R2677:11
Ta
b
le
 4
 
D
at
ab
as
e 
va
ri
ab
le
s 
fo
r 
ea
ch
 M
EN
1 
m
an
if
es
ta
ti
o
n
. G
en
er
al
 d
at
a:
 p
at
ie
n
t 
id
en
ti
fi
ca
ti
o
n
 n
u
m
b
er
, d
at
e 
o
f 
b
ir
th
, g
en
d
er
, f
am
ily
 id
en
ti
fi
ca
ti
o
n
 n
u
m
b
er
, d
at
e 
o
f 
d
ea
th
, c
au
se
 o
f 
d
ea
th
. M
EN
1 
d
at
a:
 d
at
e 
M
EN
1 
d
ia
g
n
o
si
s,
 b
as
is
 M
EN
1 
d
ia
g
n
o
si
s,
 M
EN
1g
en
et
ic
 a
n
al
ys
is
, M
EN
1 
m
u
ta
ti
o
n
.
B
io
ch
e
m
ic
a
la
Im
a
g
in
g
a
S
u
rg
e
ry
a
P
a
th
o
lo
g
y
a
M
e
d
ic
a
ti
o
n
a
p
H
PT
C
al
ci
u
m
 (
io
n
iz
ed
/t
o
ta
l)
 
PT
H
A
lb
u
m
in
25
-O
H
 v
it
am
in
 D
C
o
n
ve
n
ti
o
n
al
 im
ag
in
g
:
N
ec
k 
u
lt
ra
so
u
n
d
/C
T/
M
R
I (
n
u
m
b
er
 o
f 
ab
n
o
rm
al
it
ie
s)
Fu
n
ct
io
n
al
 im
ag
in
g
:
Sc
in
ti
g
ra
p
h
y
Su
rg
er
y
Ty
p
e 
o
f 
su
rg
er
y
Pa
ra
th
yr
o
id
 
au
to
tr
an
sp
la
n
t
Th
ym
ec
to
m
y
C
o
m
p
lic
at
io
n
s
N
u
m
b
er
 o
f 
p
ar
at
h
yr
o
id
s
H
is
to
p
at
h
o
lo
g
y
1,
25
 v
it
am
in
 D
C
al
ci
u
m
 s
u
p
p
le
ti
o
n
C
in
ac
al
ce
t
N
ET
s 
(p
an
cr
ea
s,
 
d
u
o
d
en
u
m
, 
st
o
m
ac
h
, l
u
n
g
, 
th
ym
u
s)
G
as
tr
in
G
lu
co
se
In
su
lin
Pr
o
-i
n
su
lin
C
-p
ep
ti
d
e
G
lu
ca
g
o
n
Pa
n
cr
ea
s 
p
o
ly
p
ep
ti
d
e
G
H
R
H
V
IP
Se
ro
to
n
in
 in
 
th
ro
m
b
o
cy
te
s
24
-h
 u
ri
n
ar
y 
5-
H
IA
A
C
h
ro
m
o
g
ra
n
in
 A
N
SE
72
-h
 f
as
ti
n
g
 t
es
t
C
o
n
ve
n
ti
o
n
al
:
A
b
d
o
m
in
al
: M
R
I/C
T/
g
as
tr
o
d
u
o
d
en
o
sc
o
p
y/
EU
S 
(n
u
m
b
er
, s
iz
e 
an
d
 lo
ca
ti
o
n
 o
f 
N
ET
s,
 
m
et
as
ta
se
s)
Th
o
ra
ci
c:
 M
R
I/C
T 
(n
u
m
b
er
, s
iz
e 
an
d
 lo
ca
ti
o
n
 
o
f 
N
ET
s,
 m
et
as
ta
se
s)
Fu
n
ct
io
n
al
:
So
m
at
o
st
at
in
 r
ec
ep
to
r 
sc
in
ti
g
ra
p
h
y
PE
T/
C
T 
(n
u
m
b
er
, s
iz
e 
an
d
 lo
ca
ti
o
n
 o
f 
N
ET
s,
 
m
et
as
ta
se
s)
Su
rg
er
y
O
rg
an
Ty
p
e 
o
f 
su
rg
er
y
Ly
m
p
h
 n
o
d
e 
d
is
se
ct
io
n
M
et
as
ta
se
ct
o
m
y
C
o
m
p
lic
at
io
n
s
N
u
m
b
er
 o
f 
N
ET
s 
p
er
 o
rg
an
/
p
ar
t 
o
f 
o
rg
an
Si
ze
 o
f 
th
e 
la
rg
es
t 
N
ET
Im
m
u
n
o
h
is
to
ch
em
is
tr
y:
• 
G
as
tr
in
• 
In
su
lin
e
• 
G
lu
ca
g
o
n
• 
Pa
n
cr
ea
s 
p
o
ly
p
ep
ti
d
e
• 
C
h
ro
m
o
g
ra
n
in
 A
• 
Sy
n
ap
to
p
h
ys
in
• 
O
th
er
M
it
o
si
s 
p
er
 1
0 
H
PF
K
i-
67
Ly
m
p
h
 n
o
d
e 
m
et
as
ta
se
s
O
th
er
 m
et
as
ta
se
s
R
-s
ta
tu
s
PP
I
In
su
lin
SU
-d
er
iv
at
iv
es
O
th
er
 o
ra
l 
an
ti
d
ia
b
et
ic
s
So
m
at
o
st
at
in
 a
n
al
o
g
s
C
h
em
o
th
er
ap
y
Pi
tu
it
ar
y 
Pr
o
la
ct
in
IG
F-
1
TS
H
FT
4
C
o
rt
is
o
l (
b
as
al
/m
id
n
ig
h
t)
A
C
TH
LH FS
H
Te
st
o
st
er
o
n
e
SH
B
G
Es
tr
ad
io
l
D
ex
am
et
h
as
o
n
 
su
p
p
re
ss
io
n
 t
es
t
C
o
n
ve
n
ti
o
n
al
 im
ag
in
g
:
M
R
I/C
T 
(n
u
m
b
er
, s
iz
e 
an
d
 c
o
n
si
st
en
cy
 o
f 
ab
n
o
rm
al
it
ie
s)
Su
rg
er
y
Ty
p
e 
o
f 
su
rg
er
y
C
o
m
p
lic
at
io
n
s
N
u
m
b
er
 o
f 
ad
en
o
m
as
Si
ze
 a
d
en
o
m
as
Ty
p
e 
o
f 
ad
en
o
m
a 
(s
o
lit
ar
y/
cy
st
ic
)
Im
m
u
n
o
h
is
to
ch
em
is
tr
y:
• 
Pr
o
la
ct
in
• 
G
H
• 
FS
H
• 
LH
• 
TS
H
• 
A
C
TH
• 
O
th
er
Pr
o
lif
er
at
io
n
R
-s
ta
tu
s
So
m
at
o
st
at
in
 a
n
al
o
g
s
Pe
g
iv
so
m
an
t
D
o
p
am
in
e 
ag
o
n
is
t
V
as
o
p
re
ss
in
 a
n
al
o
g
G
lu
co
co
rt
ic
o
id
H
o
rm
o
n
e 
re
p
la
ce
m
en
t 
th
er
ap
y
So
m
at
ro
p
in
Te
st
o
st
er
o
n
e
Th
yr
eo
m
im
et
ic
 a
g
en
ts
K
et
o
co
n
az
o
l
M
et
yr
ap
o
n
This work is licensed under a Creative Commons 
Attribution-NonCommercial-NoDerivatives 4.0 
International License.
https://doi.org/10.1530/EC-18-0359
https://ec.bioscientifica.com © 2018 The authors
Published by Bioscientifica Ltd
D-J van Beek et al. ‘Quality in, quality out’ EBM 
promoted by MEN1
R2687:11
were minimized. Nevertheless, prospective data collection 
will further reduce missing data.
Time aspects
Longitudinal studies covering a long time span, might 
encounter changes in care due to increased technology 
and medical knowledge. In case variations in care or 
measurement of determinants or outcomes lead to 
systematic differences between patients over time, 
detection bias exists. Considering the numerous 
manifestations and the longitudinal study design, 
detection bias is lurking for all MEN1 manifestations, 
since biochemical and radiological diagnostics have 
gained increased sensitivity and specificity over the years. 
With an increase in frequency and quality of screening, 
manifestations are detected in earlier disease stages. 
Stratifying patients into birth cohorts, to minimize the 
effects of detection bias, has been previously performed 
in a longitudinal study (23). Nevertheless, by including 
patients from 1990 onward, differences in diagnostic 
opportunities and therapies are reduced, compared to 
studies including patients over a longer time span.
The DMSG contributions to patient care
Up till now, publications from the retrospective database 
have already answered many of our research questions 
and clinical management has changed Table  5 (4, 6, 7, 
14, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 
38, 39). Moreover, the retrospective study design proved 
to be suitable, since a long latency between exposure 
and outcome exists. Most important findings from the 
DMSG research include the decreased life expectancy, 
the natural course of NETs (lung, thymus and pancreas) 
and pituitary adenomas, the effect of periodical screening 
and the surgical outcomes including complications of 
nonfunctioning pancreatic NETs (4, 14, 24, 26, 30, 33, 
35). Another example from our database is the increased 
breast cancer risk for women with MEN1 compared to the 
general population (Risk Ratio of 2.8) (6).
Current state and future perspectives
Designing a prospective database
Prospective data collection will further reduce the number 
of missing data, increase the quality of data, enable the 
collection of baseline characteristics and unknown A
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Table 5 DMSG contributions to clinical care.
Title Study objectives Outcomes/new insights
Multiple endocrine neoplasia type 1 
(MEN1): its manifestations and effect 
of genetic screening on clinical 
outcome (7)
To determine the effect of genetic screening 
on outcome in multiple endocrine 
neoplasia type 1 (MEN1)
Genetic diagnosis is associated with less morbidity at 
diagnosis and at follow-up
Early genetic diagnosis might therefore lead to 
improvement of long-term outcome
Primary hyperparathyroidism in MEN1 
patients: a cohort study with 
long-term follow-up on preferred 
surgical procedure and the relation 
with genotype (25)
To identify the optimal surgical strategy for 
multiple endocrine neoplasia type 1 
(MEN1)-related primary 
hyperparathyroidism (pHPT)
To describe the course of postoperative 
hypoparathyroidism and to assess whether 
genotype is associated with persistent/
recurrent pHPT
SPTX with bilateral transcervical thymectomy is the 
procedure of choice for MEN1-related pHPT. Genotype 
seems to affect the chance of recurrence. Postoperative 
hypoparathyroidism lasting 6 months or more should not 
be considered permanent in MEN1
Low accuracy of tumor markers for 
diagnosing pancreatic neuroendocrine 
tumors in multiple endocrine 
neoplasia type 1 patients (14)
To assess the diagnostic accuracy of 
chromogranin A (CgA), pancreatic 
polypeptide (PP), and glucagon for  
pNET in MEN1
The diagnostic accuracy of the tumor markers CgA, PP, and 
glucagon for pNET in MEN1 is low
Natural course and survival of 
neuroendocrine tumors of thymus and 
lung in MEN1 patients (26)
To assess prevalence, tumor growth, and 
survival of Thymus and lung NETs in an 
unselected MEN1 population with 
long-term follow-up
In MEN1 patients, Thymus NETs almost exclusively occurred 
in males and had a very low prevalence and a high 
mortality. Lung NETs occurred more often than previously 
thought, had an indolent course, and occurred equally in 
both sexes. Tumor growth in males was double compared 
with female patients
Breast cancer predisposition in multiple 
endocrine neoplasia type 1 (6) 
To clarify the role of MEN1 in human breast 
cancer
To assess the incidence of breast cancer in 
the Dutch longitudinal MEN1 database
Female patients with MEN1 are at increased risk for breast 
cancer
Our observations indicate that MEN1 mutations are 
involved in human breast carcinogenesis
Intensified breast cancer screening at a relatively young 
age should be considered in female patients with MEN1
Thyroid incidentalomas in patients  
with multiple endocrine neoplasia 
type 1 (28)
To assess the prevalence of thyroid 
incidentalomas in MEN1 patients compared 
with nonMEN1 patients
To verify whether thyroid tumorigenesis is 
MEN1-related
MEN1 patients do not have a higher prevalence of thyroid 
incidentalomas compared with primary 
hyperparathyroidism patients without the diagnosis of 
MEN1. Menin was expressed in the thyroid tumors of 
MEN1 patients
No association of blood type O with 
neuroendocrine tumors in multiple 
endocrine neoplasia type 1 (29)
To assess the association between blood type 
O and the occurrence of neuroendocrine 
tumors in the national Dutch MEN1 cohort
An association between blood type O and the occurrence 
of neuroendocrine tumors in MEN1 patients was not 
confirmed. For this reason, the addition of the blood 
type to screening and surveillance practice seems not to 
be of additional value for identifying MEN1 patients at 
risk for the development of neuroendocrine tumors, 
metastatic disease, or a shortened survival
Long-term natural course of pituitary 
tumors in patients  
with MEN1: results from the 
DutchMEN1 Study Group  
(DMSG) (30)
To assess the results of systematic pre-
symptomatic PIT screening and subsequent 
long-term follow-up of PITs with emphasis 
on nonfunctioning microadenomas 
diagnosed by screening
Systematic pre-symptomatic screening for PIT in patients 
with MEN1 predominantly results in detection of 
nonfunctioning microadenomas. Prolactinoma in patients 
with MEN1 responded well to medical treatment. 
Microadenomas grew only occasionally and after many 
years without clinical consequences. Frequent magnetic 
resonance imaging follow-up of nonfunctioning 
microadenomas in the context of MEN1 and sporadically 
occurring PITs therefore seems debatable
Impact of delay in diagnosis in 
outcomes in MEN1: results from the 
Dutch MEN1 Study Group (31)
To assess whether there is a lag time from 
MEN1 diagnosis of the index case to MEN1 
diagnosis of family members
To determine whether this lag time was 
associated with an increased morbidity and 
mortality risk
There is a clinically relevant delay in MEN1 diagnosis in 
families because of a lag time between the diagnosis of 
an index case and the rest of the family. More emphasis 
should be placed on the conduct of proper counseling 
and genetic testing in all eligible family members
Robot-assisted spleen preserving 
pancreatic surgery in MEN1  
patients (32) 
To describe robot-assisted and laparoscopic 
spleen-preserving pancreatic surgery in 
MEN1 patients, and to compare both 
techniques
Minimally invasive spleen-preserving surgery in  
MEN1 patients is safe and feasible. Patients who 
underwent robot-assisted surgery did not require 
conversion to open surgery
(Continued)
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Table 5 Continued.
Title Study objectives Outcomes/new insights
Early and late complications after 
surgery for MEN1-related 
nonfunctioning pancreatic 
neuroendocrine tumors (33)
To estimate short and long-term morbidity 
after pancreatic surgery for multiple 
endocrine neoplasia type 1 (MEN1)-related 
nonfunctioning pancreatic neuroendocrine 
tumors (NF-pNETs)
MEN1 NF-pNET surgery is associated with high rates of 
major short and long-term complications. Current 
findings should be taken into account in the shared 
decision-making process when MEN1 NF-pNET surgery is 
considered
MEN1 redefined, a clinical  
comparison of mutation-positive  
and mutation-negative  
patients (4)
To describe and compare the clinical course 
of MEN1 mutation-negative patients with 
two out of the three main MEN1 
manifestations and mutation-positive 
patients during long-term follow-up
Mutation-positive and mutation-negative MEN1 patients 
have a different phenotype and clinical course. Mutation-
negative patients develop MEN1 manifestations at higher 
age and have a life expectancy comparable with the 
general population. The apparent differences in clinical 
course suggest that MEN1 mutation-negative patients do 
not have true MEN1, but another MEN1-like syndrome or 
sporadic co-incidence of two neuro-endocrine tumors
Prognostic factors for survival of MEN1 
patients with duodenopancreatic 
tumors metastatic to the liver: results 
from the DMSG (34)
To determine overall survival and prognostic 
factors for patients with liver metastases 
from DP-NETs
Despite the fairly indolent course of DP-NET liver 
metastases in MEN1 patients, half of the population was 
deceased after 10 years. Sex and tumor load at diagnosis 
of liver metastases are possible prognostic factors for 
worse survival
Management of MEN1 related 
nonfunctioning pancreatic NETs: a 
shifting paradigm: results from the 
DutchMEN1 Study Group (35)
To assess if surgery for multiple endocrine 
neoplasia type 1 (MEN1) related 
nonfunctioning pancreatic neuroendocrine 
tumors (NF-pNETs) is effective for 
improving overall survival and preventing 
liver metastasis
MEN1 patients with NF-pNETs <2 cm can be managed by 
watchful waiting, hereby avoiding major surgery without 
loss of oncological safety. The beneficial effect of a 
surgery in NF-pNETs 2 to 3 cm requires further research. In 
patients with NF-pNETs >3 cm, watchful waiting seems 
not advisable
MEN1-dependent breast cancer: 
indication for early screening?  
Results from the Dutch MEN1 Study 
Group (36)
To assess whether other risk factors are 
involved to identify MEN1 at greatest risk 
for early-onset elevated breast cancer
The increased breast cancer risk in MEN1 carriers was not 
related to other known breast cancer risk factors or 
familial cancer history, and therefore breast cancer 
surveillance from the age of 40 years for all women with 
MEN1 is justifiable
Prognostic value of WHO grade in 
pancreatic neuro-endocrine tumors in 
multiple endocrine neoplasia type 1: 
results from the DutchMEN1 Study 
Group (38)
To assess the prognostic value of WHO grade 
in MEN1-related pancreatic neuroendocrine 
tumors
High mitotic count is correlated with poor prognosis in 
MEN1 patients with large nonfunctioning pNETs
Long-term natural course of small 
nonfunctional pancreatic 
neuroendocrine tumors in  
MEN1-results from the Dutch MEN1 
Study Group (24)
To assess long-term natural history of small 
NF-pNETs and its modifiers in the Dutch 
MEN1 population
The majority of small NF-pNETs are stable at long-term 
follow-up, irrespective of the underlying MEN1 genotype. 
A subgroup of tumors is slowly growing but cannot be 
identified on clinical grounds. In this subgroup, tumors 
with missense mutations exhibited faster growth. 
Additional events appear necessary for pNETs to progress. 
Future studies should be aimed at identifying these 
molecular driving events, which could be used as 
potential biomarkers
Expression of p27Kip1 and p18Ink4c in 
human multiple endocrine neoplasia 
type 1-related pancreatic 
neuroendocrine tumors (39)
To assess the role of role p27Kip1 and 
p18Ink4c in MEN1-related pancreatic 
neuroendocrine tumor development
These findings indicate that loss of p18Ink4c, but not 
p27Kip1, is a common event in the development of 
MEN1-related pNETs. Restoration of p18Ink4c function 
through CDK4/6 inhibitors could be a therapeutic option 
for MEN1-related pNETs
High fear of disease occurrence is 
associated with low quality of life in 
patients with multiple endocrine 
neoplasia type 1: results from the 
Dutch MEN1 Study Group (41)
To assess whether MEN1 leads to 
psychological distress because of fear of 
disease occurrence (FDO), and affects 
quality of life
The majority of patients with MEN1 have FDO for 
themselves and even more for their relatives. This 
psychological distress is associated with a lower 
health-related quality of life. Therefore, in the medical 
care for MEN1, emphasis should also be placed on FDO 
and quality of life
DNA methylation profiling in MEN1-
related pancreatic neuroendocrine 
tumors reveals a potential epigenetic 
target for treatment (42)
To determine promoter methylation profiles 
in MEN1-related pNETs 
 
Promoter hypermethylation is a frequent event in 
MEN1-related and sporadic pNETs. Targeting DNA 
methylation could be of therapeutic value in MEN1 
patients with advanced pNETs
CgA, chromogranin A; DMSG, Dutch MEN Study Group; DP-NET, duodenopancreatic neuroendocrine tumor; FDO, fear of disease occurrence; MEN1, 
multiple endocrine neoplasia type 1; NET, neuroendocrine tumor; NF-pNETs, nonfunctioning pancreatic neuroendocrine tumor; pHPT, primary 
hyperparathyroidism; PIT, pituitary; pNET, pancreatic neuroendocrine tumor; PP, pancreatic polypeptide; SPTX, subtotal parathyroidectomy.
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confounders. Therefore, the database is continued 
prospectively to enhance future MEN1 research based on 
the outcomes of the retrospective database. The design 
of the prospective database focuses on user-friendliness 
by using a new Web-based platform, which offers the 
opportunity to physicians to enter data during routine 
care and to automatically capture laboratory values from 
patient hospital records. Consequently, according to 
research findings, new research questions and advances 
in diagnostic and therapeutic regimen, several variables 
are added such as the breast cancer screening, bone 
density measurements, nuclear imaging and therapy and 
Table 6 DMSG overview of study phases and recommendations.
Study phase Recommendation
1. Formulating research questions
 Formulate research questions Involvement of patient advocacy group
2. Patient inclusion
 a. Increase sample size National multicenter collaboration and study group
 b. Identify patients • Diagnosis according to clinical practice guidelines
• Standardized identification method in participating centers
 c. Maximize patient enrolment • Formulate patient relevant study aims
• Involvement of patient advocacy group
Recruitment of patients among members
1. Familiarize medical research among members
 d. Maintain patient participation • Continue registry entry in new treatment center
• Optimize physician-patient relation in routine clinical care
• Patient advocacy group
Distribute research findings among patients
2. Yearly patient and specialist meetings
3. Data storage and data collection
 a. Data storage • Web-based database
• Maintain confidentiality in accordance with local legislation
 b. Database design • Consider study design
• Consider epidemiologic type of research questions
• Develop a disease-specific framework
 c. Variable selection • Raw data
• Select disease-related variables
• Reach consensus on data in study group
• Plan how variables, such as laboratory values, should be collected in dif-
ferent hospitals
 d. Data collection • Develop a central protocol to facilitate standardized data collection
• Minimize number of data collectors at a time
4. Designing a prospective database based on outcomes of the retrospective database
 a. User-friendliness
 b. Supranational collaboration
 c. Continuously update database
• Automatic data capture from hospital records
• Add indicator variables of manifestations for cross-sectional identification 
of patients to plan supranational studies
• Include new variables based on new research questions or advances in 
care
5. Biobanking
 a. National collaboration • Establish central organization/collaboration between UMCs
• Create centralized biobanking protocol including all phases: collection, 
pre-analysis, registration, processing and storage of the samples
• Sites of tissue collection and storage
E.g. in individual UMC biobanks
 b. Decide on materials • Choices on which patient materials to collect
Blood, tissue, feces, urine and others
• Plan on how to collect materials
Routine patient care or in research setting
 c. Link to clinical data • Preferably implement link to clinical data
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surgical techniques. In addition, some indicator variables 
are added for the manifestations, so cross-sectional 
prevalence estimates can easily be obtained, which are 
useful for planning supranational research projects and 
imaginably a global RCT in the future. In addition to 
clinical data collection, patient material is obtained and 
stored in the biobanks of all UMCs to enable future basal 
and translational research. Assembled MEN1 patient 
materials include blood (serum, EDTA and citrate 
plasma and DNA) and tissue (formalin-fixed paraffin-
embedded and fresh frozen) of biopsies and resected 
specimen (40). Materials are preferably obtained during 
routine patient care.
The Parelsnoer Institute
This clinical database and biobank initiative is now part 
of the Parelsnoer Institute (PSI) (http://www.parelsnoer.
org/page/en/Home), which is part of the Netherlands 
Federation of UMCs (40). Within the framework of PSI, 
individual UMC clinical biobanks store patient materials 
according to a standardized national biobanking protocol, 
covering all phases of biobanking: collection, pre-analysis, 
registration, processing and storage of the samples (40). 
These data are centrally stored and linked to the clinical 
patient data. Clinical data are either manually captured, 
however, automatic data capture options are available 
for certain variables, such as laboratory tests (40). The 
connection between clinical and biobank data offers the 
unique opportunity to study genetic and epigenetic factors 
driving hereditary NETs. Identification of these factors 
in familial tumors, could in the future be extrapolated 
to sporadic NETs to identify NETs with an unfavorable 
prognosis and offer specific new targets for therapeutic 
opportunities.
Conclusion
Guided by our MEN1 experiences, we propose a stepwise 
approach from clinical research questions to scientific 
answers (Table  6). This experience can guide others 
planning to start a database for rare diseases. Involvement 
of the patients themselves from the beginning leads to 
meaningful research questions guiding clinical care and, 
in addition, increases the participation rate, thereby 
minimizing selection bias. Thereafter, the protocolized 
and standardized process of data collection and data 
storage into a disease-specific database enables the 
collection of homogeneous data and reducing information 
bias. Ongoing prospective clinical data collection and the 
collection of biobank materials has commenced in 2016, 
which will further increase the quality of the data and 
enables clinical epidemiological and translational research 
in the near future. This will directly impact patient care 
and provide new insights into MEN1 in the future.
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